Search Results

You are looking at 1 - 10 of 207 items for :

  • "long-term follow-up" x
  • Refine by Access: All content x
Clear All
Free access

Birke Bausch, Ulrich Wellner, Dirk Bausch, Francesca Schiavi, Marta Barontini, Gabriela Sanso, Martin K Walz, Mariola Peczkowska, Georges Weryha, Patrizia Dall'Igna, Giovanni Cecchetto, Gianni Bisogno, Lars C Moeller, Detlef Bockenhauer, Attila Patocs, Karoly Rácz, Dmitry Zabolotnyi, Svetlana Yaremchuk, Iveta Dzivite-Krisane, Frederic Castinetti, David Taieb, Angelica Malinoc, Ernst von Dobschuetz, Jochen Roessler, Kurt W Schmid, Giuseppe Opocher, Charis Eng, and Hartmut P H Neumann

al . 2013 ). Our data emphasizes the need for meticulous short- and long-term follow-up. Tumor recurrences occur early, within the first year, but they can occur 30 years after primary surgery ( Fig. 2 A). Ten percent develop malignant paraganglial

Free access

Jae Hyun Park and Jong Ho Yoon

without RAI ablation as initial therapy ( Vaisman et al. 2011 , Durante et al. 2012 ). The few recurrences that develop during long-term follow-up are readily detected by neck ultrasonography and treated without affecting survival, because salvage

Open access

Ha Nguyen, Komal Shah, Steven G Waguespack, Mimi I Hu, Mouhammed Amir Habra, Maria E Cabanillas, Naifa L Busaidy, Roland Bassett, Shouhao Zhou, Priyanka C Iyer, Garrett Simmons, Diana Kaya, Marie Pitteloud, Sumit K Subudhi, Adi Diab, and Ramona Dadu

established, leading to much difficulty in obtaining accurate data on incidence and prevalence as well as solidifying recommendations of treatment and long-term follow-up. In addition, most studies were small size and multi-institutional with inconsistent

Restricted access

Marta Araujo-Castro, César Mínguez Ojeda, Rogelio García Centeno, María-Carmen López-García, Cristina Lamas, Felicia Alexandra Hanzu, Mireia Mora, María del Castillo Tous, Pablo Rodríguez de Vera Gómez, Paola Parra Ramírez, Cristina Alvarez-Escola, Concepción Blanco Carrera, Rebeca Barahona San Millán, Mónica Recasens, Nuria Valdés, Paola Gracia Gimeno, Paz de Miguel Novoa, Almudena Vicente, Laura Manjón, Iñigo García Sanz, Theodora Michalopoulou, and María Calatayud

with confirmed histological diagnosis of pheochromocytoma or paraganglioma and with available clinical and biochemical data before and after surgery (in the immediate and long-term follow-up) were included. Biochemical demonstration of catecholamine

Free access

Christina Wei and Elizabeth C Crowne

( https://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers/long-term-follow-up#heading-Two ). An estimated 1 in 640–700 young adults in the United States and United Kingdom is a childhood cancer survivor ( Campbell et al

Open access

G Carreno, J K R Boult, J Apps, J M Gonzalez-Meljem, S Haston, R Guiho, C Stache, L S Danielson, A Koers, L M Smith, A Virasami, L Panousopoulos, M Buchfelder, T S Jacques, L Chesler, S P Robinson, and J P Martinez-Barbera

Introduction Adamantinomatous craniopharyngiomas (ACPs) are benign tumours of the sellar region that are associated with high morbidity and increased mortality in long-term follow-up. They constitute the most common non-neuroepithelial brain

Free access

D Cecchin, F Lumachi, M C Marzola, G Opocher, C Scaroni, P Zucchetta, F Mantero, and F Bui

were established according to clinical, biochemical and histological data and on the basis of a long-term follow-up. Sensitivity was defined as (TP)/(TP + FN), specificity as (TN)/(TN + FP), positive predictive value (PPV) as (TP)/(TP + FP

Free access

Elina Ritvonen, Eliisa Löyttyniemi, Pia Jaatinen, Tapani Ebeling, Leena Moilanen, Pirjo Nuutila, Ritva Kauppinen-Mäkelin, and Camilla Schalin-Jäntti

thus provide novel information regarding the evolving causes of death in acromegaly during very long-term follow-up. Whether cancer incidence is increased in acromegaly and whether cancer deaths are increased in acromegaly is still a matter of debate

Restricted access

F Lee, D B Siders, T A McHugh, M H Solomon, and D M Mayman

Abstract

Our previously reported non-randomized clinical trial proved the ability of preoperative androgen ablation therapy (AAT) to decrease positive surgical margins and to downstage a subset of biopsy-proven stage T3 cancer. The present study focuses on the progression of the disease in this group over a 3-year (mean) period.

For 140 consecutive radical prostatectomies, this study evolved into comparisons of three groups: (1) 124 patients with clinically confined cancer given AAT; (2) 121 patients with clinical stage B not given AAT; (3) 16 patients with proven stage T3 by transrectal ultrasound-guided biopsy and given AAT.

Comparison of AAT with no AAT resulted in positive surgical margin rates of 14.5% vs 47.5%. For known stage T3/C, a 44% downstaging occurred with no evidence of diseases at 40 months (mean). The 56% with non-confined (persistent) cancer after AAT had progression usually by 1 year. Specimen-confined disease had progression as measured by prostate specific antigen of 18% for AAT vs 10% when no AAT was given.

Neoadjuvant AAT before radical prostatectomy decreased by threefold the rate of positive surgical margins. Long-term follow-up of these patients is to continue since present results are very promising.

Endocrine-Related Cancer (1996) 3 171-177

Free access

Dheeraj Karamchandani, Ramiro Arias-Amaya, Nora Donaldson, Jackie Gilbert, and Klaus-Martin Schulte

Kidney transplantation and the associated immune suppression are associated with a significantly increased risk of developing cancer during long-term follow-up. Thyroid cancer has been recognised as a potential post-transplant risk but has not yet been subject of a focused review. We therefore performed a meta-analysis on data of 50 861 patients with a total follow-up of 198 595 patient-years and identified a 6.9-fold higher standardised incidence ratio (95% confidence interval 5.6–8.7, P<0.001) of thyroid cancer post renal transplantation as compared with a non-transplant group. All such cancers were of papillary type as far as histopathology was known. The mean time to discovery was 6.0 years post transplantation. This puts thyroid cancer into the group of high cancer risk following solid organ transplantation which already includes cervical cancer, non-melanoma skin cancer, oral and lip cancer and haematological malignancies. It is unclear what causes the increased cancer incidence. Inclusion of thyroid ultrasound in long-term post-transplant evaluation may help to ensure timely recognition of this condition.